Evidence mapPaperPMID 18779236Full record

Trial reportThe New England journal of medicine2008

Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, William V Tamborlane, Roy W Beck, Bruce W Bode, Bruce Buckingham, H Peter Chase, Robert Clemons, Rosanna Fiallo-Scharer, Larry A Fox, Lisa K Gilliam and 17 more

13 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 13 registered trials, which are not on this map. Cited by 631 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
631citing papers in PubMed, 10 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01524705 phase4completedstarted 2012, after this paper: background citation

FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR

Ran2012Enrolled102Registered outcomes4Posted comparisons3ConditionsType 2 DiabetesArmsexenatide, Insulin glargine, Metformin, Prandial insulin
Open the trial in the graph
NCT01881828 phase3completedstarted 2013, after this paper: background citation

A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes

Ran2013Enrolled164Registered outcomes16Posted comparisons0ConditionsType 1 DiabetesArmsMetformin (glucophage), oral placebo
Open the trial in the graph
NCT00406133 phase3completednot on this map

A Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) in the Management of Type 1 Diabetes

TypeinterventionalSponsorJaeb Center for Health ResearchRan2006 to 2009Enrolled451ConditionsType 1 DiabetesArmsContinuous glucose monitor
NCT01083433 nacompletednot on this mapstarted 2010, after this paper: background citation

Intensive Diabetes Clinic and Intermittent Continuous Glucose Monitoring in Adolescents With Type 1 Diabetes Mellitus in Poor Glycemic Control

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2010 to 2011Enrolled68ConditionsType 1 Diabetes MellitusArmsDiabetes related psychological counseling and education, Continuous Glucose Monitor
NCT01474889 nacompletednot on this mapstarted 2011, after this paper: background citation

Effect of Real-Time Continuous Glucose Monitoring on Glucose Counterregulation in Long Standing Type 1 Diabetes

TypeinterventionalSponsorUniversity of PennsylvaniaRan2011 to 2021Enrolled37ConditionsHypoglycemia Unawareness, Type 1 Diabetes, HealthyArmsRT-CGM
NCT01741467 nacompletednot on this mapstarted 2012, after this paper: background citation

The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes

TypeinterventionalSponsorWalter Reed National Military Medical CenterRan2012 to 2016Enrolled110ConditionsPre-diabetes, Impaired Glucose ToleranceArmsRT-CGM
NCT01908530 nacompletednot on this mapstarted 2013, after this paper: background citation

Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes

TypeinterventionalSponsorImperial College LondonRan2013 to 2018Enrolled26ConditionsDiabetes MellitusArmsMicroprobe glucose sensor
NCT02092051 nacompletednot on this mapstarted 2014, after this paper: background citation

A Randomized Trial of the Effect of Continuous Glucose Monitoring (CGM) in Individuals With Type 1 Diabetes Treated With Multiple Daily Insulin Injections (MDI)

TypeinterventionalSponsorVastra Gotaland RegionRan2014 to 2016Enrolled161ConditionsDiabetes Mellitus, Type 1ArmsContinuous glucose monitoring with DexCom G4 platina
NCT03186300 nacompletednot on this mapstarted 2017, after this paper: background citation

Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)

TypeinterventionalSponsorInstitut d'Investigació Biomèdica de Girona Dr. Josep TruetaRan2017 to 2018Enrolled8ConditionsDiabetes Mellitus, Type 1ArmsPEPPER system
NCT03199638 nacompletednot on this mapstarted 2016, after this paper: background citation

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

TypeinterventionalSponsorNemours Children's ClinicRan2016 to 2017Enrolled14ConditionsDiabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System DiseasesArmsGlutamine vs. Placebo, Exercise
NCT03505268 naunknown statusnot on this mapstarted 2018, after this paper: background citation

The Impact of Telehealthcare Intervention on Glycemic Control in Children and Adolescents With Type 1 Diabetes

TypeinterventionalSponsorAssuta Hospital SystemsRan2018 to 2019Enrolled75ConditionsType 1 Diabetes MellitusArmsTelemedicine
NCT03849755 nacompletednot on this mapstarted 2018, after this paper: background citation

Patient Empowerment Through Predictive Personalised Decision Support(PEPPER)-Validation Study.

TypeinterventionalSponsorInstitut d'Investigació Biomèdica de Girona Dr. Josep TruetaRan2018 to 2019Enrolled58ConditionsDiabetes Mellitus, Type 1ArmsPEPPER system
NCT07548372 narecruitingnot on this mapstarted 2026, after this paper: background citation

Supporting Primary Care Adoption, Resources, and Knowledge for Continuous Glucose Monitoring

TypeinterventionalSponsorMontefiore Medical CenterRan2026 to 2028Enrolled20,000ConditionsDiabetes MellitusArmsEnhanced CGM Interventions, Standard of Care
3 · Its place in the literature

Who cites it

631 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024
    Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

571 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group
William V Tamborlane
Roy W Beck
Bruce W Bode
Bruce Buckingham
H Peter Chase
Robert Clemons
Rosanna Fiallo-Scharer
Larry A Fox
Lisa K Gilliam
Irl B Hirsch
Elbert S Huang
Craig Kollman
Aaron J Kowalski
Lori Laffel
Jean M Lawrence
Joyce Lee
Nelly Mauras
Michael O'Grady
Katrina J Ruedy
Michael Tansey
Eva Tsalikian
Stuart Weinzimer
Darrell M Wilson
Howard Wolpert
Tim Wysocki
Dongyuan Xing

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe value of continuous glucose monitoring in the management of type 1 diabetes mellitus has not been determined.

methodsIn a multicenter clinical trial, we randomly assigned 322 adults and children who were already receiving intensive therapy for type 1 diabetes to a group with continuous glucose monitoring or to a control group performing home monitoring with a blood glucose meter. All the patients were stratified into three groups according to age and had a glycated hemoglobin level of 7.0 to 10.0%. The primary outcome was the change in the glycated hemoglobin level at 26 weeks.

resultsThe changes in glycated hemoglobin levels in the two study groups varied markedly according to age group (P=0.003), with a significant difference among patients 25 years of age or older that favored the continuous-monitoring group (mean difference in change, -0.53%; 95% confidence interval [CI], -0.71 to -0.35; P<0.001). The between-group difference was not significant among those who were 15 to 24 years of age (mean difference, 0.08; 95% CI, -0.17 to 0.33; P=0.52) or among those who were 8 to 14 years of age (mean difference, -0.13; 95% CI, -0.38 to 0.11; P=0.29). Secondary glycated hemoglobin outcomes were better in the continuous-monitoring group than in the control group among the oldest and youngest patients but not among those who were 15 to 24 years of age. The use of continuous glucose monitoring averaged 6.0 or more days per week for 83% of patients 25 years of age or older, 30% of those 15 to 24 years of age, and 50% of those 8 to 14 years of age. The rate of severe hypoglycemia was low and did not differ between the two study groups; however, the trial was not powered to detect such a difference.

conclusionsContinuous glucose monitoring can be associated with improved glycemic control in adults with type 1 diabetes. Further work is needed to identify barriers to effectiveness of continuous monitoring in children and adolescents. (ClinicalTrials.gov number, NCT00406133.)

Indexed as

AdolescentAdultAnalysis of VarianceBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin Infusion SystemsMaleBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID18779236

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 7 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.